For example, targeting of ASK1 with an ASK1 inhibitor, selonsertib, which prevented AngII-induced cardiac hypertrophy and fibrosis in mice [71], or activation of PAK1 as mentioned above, are potentially indirect means of effectively targeting Rac1-regulated pathogenic signaling in cardiomyocytes. Here, RAC1 is linked to cardiac hypertrophy.